Ge Healthcare Technologies Inc - GEHC STOCK NEWS

GE HealthCare announces its leading role in Thera4Care, a €25.3 million project aimed at revolutionizing theranostics for cancer care in Europe. The initiative brings together 29 partners from academia, clinics, SMEs, and patient advocacy groups across 14 European countries and the US. Thera4Care's goals include:

1. Expanding the European network of copper-producing isotope GMP sites
2. Developing next-generation SPECT-CT imaging scanners
3. Building AI-enabled imaging and multi-modal theranostic clinical decision support
4. Enhancing AI-based tumor quantitation for personalized dosimetry

The project, co-funded by Horizon Europe and the Innovative Health Initiative, aims to broaden patient access to theranostics by creating standardized, scalable methods for production, detection, and monitoring of key theranostic isotopes. It focuses on prostate, ovarian, pancreas cancers, and sarcomas.

GE HealthCare (Nasdaq: GEHC) has announced the completion of its Phase I clinical development program for a first-of-its-kind manganese-based macrocyclic MRI contrast agent. The results, presented at the 2024 bi-annual Contrast Media Research symposium in Oslo, Norway, showed that the agent was well tolerated with no serious adverse events or clinically relevant findings reported.

This novel contrast agent could provide an alternative to gadolinium-based agents, addressing concerns about gadolinium retention and environmental impact. The manganese-based agent has comparable relaxivity to gadolinium-based agents and is expected to be diagnostically similar. Unlike gadolinium, manganese is naturally occurring in and efficiently eliminated from the body.

The Phase I trial was conducted at Oslo University Hospital, Rikshospitalet, Norway, with partial funding from the Norwegian Research Council. GE HealthCare aims to offer more choice to radiologists and deliver a broad portfolio for personalized care and unmet patient needs.

GE HealthCare (Nasdaq: GEHC) announced FDA approval of Flyrcado (flurpiridaz F 18) injection, a novel PET radiotracer for detecting coronary artery disease (CAD). Flyrcado offers higher diagnostic efficacy compared to SPECT MPI, the current standard in nuclear cardiology. With a 109-minute half-life, it allows for off-site production and wider distribution, potentially expanding access to PET myocardial perfusion imaging (MPI).

Key advantages include:

• First practical opportunity to combine exercise stress testing with cardiac PET imaging for CAD
• Improved diagnostic accuracy for difficult-to-image patients
• Ability to rescan patients during the same session if needed

GE HealthCare (Nasdaq: GEHC) announced its latest innovations in radiation oncology to be showcased at the American Society for Radiation Oncology (ASTRO) 2024 conference. The company is presenting several AI-enhanced solutions aimed at improving the radiation therapy workflow:

1. Intelligent Radiation Therapy (iRT): Enables multi-vendor system interoperability and efficiency throughout the care continuum.

2. Revolution™ RT: A wide-bore CT platform for precision radiation therapy simulation.

3. MIM Maestro and Contour ProtégéAI+: Interoperable technologies for AI auto-contouring and improved treatment planning.

4. Prostate Volume Assist: AI software for automated prostate volume measurements.

5. StarGuide™: A digital SPECT/CT system for personalized care decisions in Theranostics.

These innovations aim to streamline workflows, reduce time to treatment, and improve patient outcomes in radiation oncology.

GE HealthCare (Nasdaq: GEHC) has unveiled enhanced Venue ultrasound systems and introduced Venue Sprint, a new portable ultrasound device for point-of-care (POCUS) applications. Venue Sprint combines powerful Venue software, AI-enabled tools, and wireless probe capability with Vscan Air handheld systems. The Venue family now offers wireless probe connectivity, advanced clinical tools, and ViewPoint 6 updates for improved efficiency.

Key features of Venue Sprint include:

• Tablet form factor for maximum portability
• Wireless Vscan Air dual-probes for flexible use
• AI-enabled resources and documentation tools
• Integration with Caption Guidance for cardiac ultrasound imaging

These innovations aim to empower clinicians to deliver care in various settings, potentially reducing health inequities and expanding access across different care areas.

GE HealthCare Technologies Inc. (Nasdaq: GEHC) has announced a cash dividend for the third quarter of 2024. The company's Board of Directors has declared a dividend of $0.03 per share of Common Stock. This dividend will be payable on November 15, 2024 to all shareholders of record as of October 18, 2024. This announcement demonstrates GE HealthCare's commitment to providing regular returns to its shareholders, albeit at a modest level.

GE HealthCare Technologies Inc. (Nasdaq: GEHC) has priced its upsized secondary public offering of 15,000,000 shares of common stock at $86.00 per share. The offering was increased from the initially announced 10,000,000 shares. GE HealthCare will not receive any proceeds from the sale. Prior to closing, GE Aerospace is expected to exchange the shares for debt held by Morgan Stanley affiliates. The selling stockholder has granted underwriters an option to purchase an additional 2,250,000 shares. Morgan Stanley and Citigroup are leading the offering, which is expected to close on September 16, 2024, subject to customary conditions.

GE HealthCare Technologies Inc. (Nasdaq: GEHC) has announced a secondary public offering of 10,000,000 shares of its common stock. The company itself is not selling any shares or receiving proceeds from the sale. Prior to the offering's closing, GE Aerospace is expected to exchange the GEHC shares for debt held by Morgan Stanley affiliates. The selling stockholder has granted underwriters an option to purchase an additional 1,500,000 shares for settlement by September 30, 2024. Morgan Stanley and Citigroup are acting as lead joint book-running managers for the offering. The company has filed an automatically effective shelf registration statement with the SEC for this offering.

GE HealthCare (Nasdaq: GEHC) announced CE marks for two innovative cardiology solutions: the Vscan Air™ SL with Caption AI™, an AI-driven handheld ultrasound system for rapid cardiac assessments, and ECG-less Cardiac CT scanning on its Revolution Apex™ platform. These technologies aim to enable more efficient and timely cardiac care at the point of service.

The Vscan Air SL with Caption AI provides real-time guidance for capturing cardiac images, even for non-experts, and includes an AutoEF feature for calculating left ventricular ejection fraction. The ECG-less Cardiac CT solution allows for cardiac imaging without an ECG signal, prioritizing patient access and speed.

Both innovations will be showcased at the European Society of Cardiology (ESC) Congress in London, August 30-September 2, 2024, along with GE HealthCare's Allia™ IGS 5 Pulse image-guided platform for interventional cardiology.